About:

Colorectal cancer is one of the world's deadliest cancers, with almost a million deaths annually. Advances in the pathophysiological and molecular understanding have increased the range of treatment options available, including endoscopic and surgical excisions, downstaging preoperative radiotherapy and systemic therapy, local ablative therapies for metastases, palliative chemotherapy, targeted therapy, and immunotherapy. Although these novel treatment options have doubled the overall survival for advanced disease, survival is still best for those with non-metastatic disease. This talk, by Dr Kai-Keen Shiu, will discuss the rationale behind and the advances in the peri-operative treatment of colonic and rectal cancers, the rationale behind and the advances in the management of operable metastatic disease, and the management of the molecular subgroups. The talk is aimed at surgical trainees at a registrar level and, specifically, those preparing for the FRCS (General Surgery) Exit Exam.

Topics:

• Importance of the MDT
• Rationale behind and advances in peri-operative treatment of colon cancer
• Rationale behind and advances in peri-operative treatment of rectal cancer
• Rationale behind and advances in the management of operable metastatic colorectal cancer
• Management of molecular subgroups: KRAS/NRAS/BRAF/MMR-deficient colorectal cancers

Suitable for:

• ST3 and above trainees in GeneralSurgery.
• ST3 and above trainees in ColorectalSurgery.
• Trainees preparing for the FRCS(General Surgery) Exit Exam.
• Post CCT trainees in General Surgery.
• Post CCT trainees in Colorectal Surgery.
• Post CCT trainees in Rectal Robotic Surgery.

Speaker: